866-997-4948(US-Canada Toll Free)

Global Ulcerative Colitis Market 2016-2020

Published By :

Technavio

Published Date : May 2016

Category :

Metabolic Disorders

No. of Pages : 67 Pages

About Ulcerative Colitis

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that affects the colon and rectum. Inflammation and ulcers are formed in the innermost lining of the colon and rectum, resulting in the production of pus and mucous. Based on the extent of inflammation and the location, ulcerative colitis can be of different types: ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. Abdominal cramps, diarrhea, and rectal bleeding are among the common symptoms observed in individuals with the disease. Medications such as 5-aminosalicylates, steroids, purine analogs, immunomodulators, and biologics are used to treat the disease.

Technavios analysts forecast the global ulcerative colitis market to grow at a CAGR of 6.6% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global ulcerative colitis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used to treat ulcerative colitis.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Ulcerative Colitis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AbbVie
Janssen Biotech
Merck
Takeda Pharmaceuticals

Other prominent vendors
Abbott
Ajinomoto Pharmaceuticals
Amgen
Arena Pharmaceuticals
AstraZeneca
Astellas Pharma
Avaxia Biologics
BioLineRx
Celgene
Cosmo Pharmaceuticals
Eisai
Ferring Pharmaceuticals
Galapagos
Genentech
Gilead Sciences
GlaxoSmithKline
Hutchison Medi Pharma
Immune Pharmaceuticals
InDex Pharmaceuticals
Kaken Pharmaceutical
Kissei Pharmaceutical
Kyowa Hakko Kirin
Lipid Therapeutics
Meda
Mitsubishi Tanabe
Mochida Pharmaceutical
Morphotek
Nestl
Pfizer
Procter & Gamble
Qu Biologics
Receptos
Salix Pharmaceuticals
Shield Therapeutics
Shire Pharmaceuticals
Sterna Biologicals
Tillotts Pharma
TopiVert
UCB
Zeria Pharmaceutical

Market driver
Increase in patient assistance programs
For a full, detailed list, view our report

Market challenge
Patent expiries
For a full, detailed list, view our report

Market trend
Rising use of biologics
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Etiology
Epidemiology
Symptoms
Diagnosis and testing
Treatment
Prognosis
Economic burden
Reimbursement scenario
PART 06: Pipeline analysis
Z-206
MD-0901
TP05
Stelara
Etrolizumab
Xeljanz
HMPL-004
Kappaproct
AJG511
AJM300
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by molecule type
Biologics
Small molecules
Biologics segment in ulcerative colitis drugs market
Small molecules segment in ulcerative colitis drugs market
PART 09: Market segmentation by dosage form
Solid
Liquid
PART 10: Market segmentation by route of administration
Oral
Parenteral
PART 11: Geographical segmentation
Global ulcerative colitis drugs market by geography 2015-2020
Ulcerative colitis drugs market in Americas
Ulcerative colitis drugs market in EMEA
Ulcerative colitis drugs market in APAC
PART 12: Market drivers
Increase in patient assistance programs
High unmet needs
Tentative approval of candidates in pipeline
PART 13: Impact of drivers
PART 14: Market challenges
High cost of drugs
Patent expiries
Adverse effects of drugs
Unknown disease etiology
PART 15: Impact of drivers and challenges
PART 16: Market trends
Growing public awareness
Rising use of biologics
Emergence of biosimilars
Strategic alliances
PART 17: Vendor landscape
Competitive scenario
Market share analysis 2015
AbbVie
Janssen Biotech
Merck
Takeda Pharmaceuticals
Other prominent vendors
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Causes of ulcerative colitis
Exhibit 03: Symptoms of ulcerative colitis
Exhibit 04: Diagnostic approach for ulcerative colitis
Exhibit 05: Treatment options for ulcerative colitis
Exhibit 06: Treatment guidelines of ulcerative colitis based on severity
Exhibit 07: Surgical procedures to treat ulcerative colitis
Exhibit 08: Global ulcerative colitis drugs market: Pipeline portfolio
Exhibit 09: Global ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 10: Snapshot of global ulcerative colitis drugs market
Exhibit 11: Five forces analysis
Exhibit 12: Global ulcerative colitis drugs market by molecule type
Exhibit 13: Global ulcerative colitis drugs market by molecule type 2015
Exhibit 14: Biologics segment in ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 15: Small molecules segment in ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 16: Global ulcerative colitis drugs market by dosage form
Exhibit 17: Global ulcerative colitis drugs market by route of administration
Exhibit 18: Global ulcerative colitis drugs market segment by geography 2015
Exhibit 19: Ulcerative colitis drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 20: Ulcerative colitis drugs market in Americas 2015-2020 ($ billions)
Exhibit 21: Ulcerative colitis drugs market in EMEA 2015-2020 ($ billions)
Exhibit 22: Ulcerative colitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Global ulcerative colitis drugs market share analysis 2015
Exhibit 26: YoY revenue comparison of top drugs for ulcerative colitis 2011-2014 ($ millions)
Exhibit 27: AbbVie: Product segmentation by revenue 2014
Exhibit 28: AbbVie: Product segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 29: AbbVie: Geographical segmentation by revenue 2014
Exhibit 30: AbbVie: YoY growth and revenue of Humira 2012-2014 ($ billions)
Exhibit 31: AbbVie: Key takeaways
Exhibit 32: Janssen Biotech: YoY growth and revenue of Remicade 2012-2014 ($ millions)
Exhibit 33: Janssen Biotech: YoY growth and revenue of Simponi/Simponi ARIA 2012-2014 ($ millions)
Exhibit 34: Janssen Biotech: Key takeaways
Exhibit 35: Merck: Business segmentation by revenue 2014
Exhibit 36: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 37: Merck: Geographical segmentation by revenue 2014
Exhibit 38: Merck: YoY growth and revenue of Remicade 2012-2014 ($ millions)
Exhibit 39: Merck: YoY growth and revenue of Simponi 2012-2014 ($ millions)
Exhibit 40: Merck: Key takeaways
Exhibit 41: Takeda Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 42: Takeda Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 44: Takeda Pharmaceuticals: Key takeaways

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *